Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 3,907 $ 2,872
General and administrative 1,204 1,333
Total operating expenses 5,111 4,205
Loss from operations (5,111) (4,205)
Other (expense) income:    
Interest expense, net (1)
Foreign exchange loss (78) (13)
Change in fair value of derivative liabilities 11
Total other (expense) income, net (78) (3)
Net loss $ (5,189) $ (4,208)
Net loss per common share, basic and diluted $ (0.64) $ (0.52)
Weighted average number of common shares outstanding, basic and diluted 8,143 8,143